

In the claims:

Kindly amend the claims as follows.

1 -18. Canceled

19 (previously amended). A recombinant DNA construct comprising:

- (i) a vector, and
- (ii) a DNA fragment encoding a chimeric filovirus protein

comprising a full-length GP1 from a first filovirus fused to a full-length GP2 from a second filovirus, wherein the COOH-terminus of said GP1 is fused to the NH₂-terminus of GP2.

20 (previously amended). The recombinant DNA construct according to claim 19 wherein said DNA fragment encodes a chimeric protein chosen from the group consisting of:

- (i) Marburg Musoke GP1/Ebola Zaire GP2,
- (ii) Ebola Zaire GP1/Marburg Musoke GP2,
- (iii) Marburg Musoke GP1/Marburg Ravn GP2, and
- (iv) Marburg Ravn GP1/Marburg Musoke GP2.

21 (original). A recombinant DNA construct according to claim 20 wherein said vector is an expression vector.

22 (original). A recombinant DNA construct according to claim 20 wherein said vector is a prokaryotic vector.

23 (original). A recombinant DNA construct according to claim 20 wherein said vector is a eukaryotic vector.

24 (original). A recombinant DNA construct according to claim 20 wherein said vector is a VEE virus replicon vector.

25 (previously amended). The recombinant DNA construct according to claim 24 wherein said construct is EBOV-MAY GP1 (aa1-501)/MBGV-MUS GP2 (aa436-681).

26 (original). The recombinant DNA construct according to claim 24 wherein said construct is MBGV-MUD GP1 (aa1-435)/EBOV-MAY GP2 (aa502-676).

27 (original). The recombinant DNA construct according to claim 24 wherein said construct is MBGV-RVN GP1 (aa1-435)/MBGV-MUS GP2 (aa436-681).

28 (original). The recombinant DNA construct according to claim 24 wherein said construct is MBGV-MUS GP1 (aa1-435)/MBGV-RVN GP2 (aa436-681).

29 (withdrawn). Self replicating RNA produced from the construct of any of claims 24-28.

30 (withdrawn). Infectious alphavirus particles produced from packaging the self replicating RNA of claim 29.

31 (withdrawn). A pharmaceutical composition comprising infectious alphavirus particles according to claim 30 in an effective immunogenic amount in a pharmaceutically acceptable carrier and/or adjuvant.

32 (Currently amended). A An isolated host cell transformed with a recombinant DNA construct according to claim 19.

33 (original). A host cell according to claim 32 wherein said host cell is prokaryotic.

34 (original). A host cell according to claim 32 wherein said host cell is eukaryotic.

35 (currently amended). A method for producing chimeric filovirus proteins comprising culturing the cells according to claim 33 under conditions such that said DNA fragment is expressed and said chimeric protein is produced and isolating said protein.

36 (currently amended). A method for producing chimeric filovirus proteins comprising culturing the cells according to claim 34 under conditions such that said DNA fragment is expressed and said chimeric protein is produced and isolating said protein..

37-48. Canceled.

49 (previously added). A recombinant DNA vector according to claim 19 wherein said DNA fragment is SEQ ID NO:1.

50 (previously added). A recombinant DNA vector according to claim 19 wherein said DNA fragment is SEQ ID NO:3.

51 (previously added). A recombinant DNA vector according to claim 19 wherein said DNA fragment is SEQ ID NO:5.

52 (previously added). A recombinant DNA vector according to claim 19 wherein said DNA fragment is SEQ ID NO:7.

53 (newly added). An immunogenic composition comprising the infectious alphavirus particles of claim 30.

54. (newly added). An isolated host cell transformed with a recombinant DNA construct according to claim 24.

55. (newly added). The host cell of claim 54 wherein said host cell is prokaryotic.

56. (newly added). The host cell of claim 54 wherein said host cell is eukaryotic.

57. (newly added). An isolated host cell transformed with a recombinant DNA construct according to claim 25.

58. (newly added). The host cell of claim 57 wherein said host cell is prokaryotic.

59. (newly added). The host cell of claim 57 wherein said host cell is eukaryotic.

60. (newly added). An isolated host cell transformed with a recombinant DNA construct according to claim 26.

61. (newly added). The host cell of claim 60 wherein said host cell is prokaryotic.

62. (newly added). The host cell of claim 60 wherein said host cell is eukaryotic.

63. (newly added). An isolated host cell transformed with a recombinant DNA construct according to claim 27.

64. (newly added). The host cell of claim 63 wherein said host cell is prokaryotic.

65. (newly added). The host cell of claim 63 wherein said host cell is eukaryotic.

66. (newly added). An isolated host cell transformed with a recombinant DNA construct according to claim 28.

67. (newly added). The host cell of claim 66 wherein said host cell is prokaryotic.

68. (newly added). The host cell of claim 66 wherein said host cell is eukaryotic.